Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 10:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 487 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Acne Clear all
Completed Not applicable Interventional Accepts healthy volunteers

RCT of an Oral Acne Supplement for Adult Women

NCT06097871
View directory record Official record
Conditions
Acne
Interventions
Skin Nutraceutical Supplement, Placebo pill
Dietary Supplement · Other
Lead sponsor
Nutraceutical Wellness Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Sep 5, 2026, 10:10 AM EDT
Withdrawn Early Phase 1 Interventional

An Alternative Dose Interval Study in Participants With Hidradenitis Suppurativa Receiving Brodalumab

NCT04249713
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Brodalumab
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Sep 5, 2026, 10:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Fractional Radiofrequency for Treatment of Acne Scars and Wrinkles

NCT05827510
View directory record Official record
Conditions
Acne, Wrinkle
Interventions
BTL-585F
Device
Lead sponsor
BTL Industries Ltd.
Industry
Eligibility
21 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Davie, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Sep 5, 2026, 10:10 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients

NCT02421172
View directory record Official record
Conditions
Hidradenitis Suppurativa (Acne Inversa)
Interventions
CJM112, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Los Angeles, California • Ormond Beach, Florida • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Sep 5, 2026, 10:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Weekly Isotretinoin Therapy Study

NCT04594759
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Isotretinoin
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
12 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced Sep 5, 2026, 10:10 AM EDT
Completed Not applicable Interventional

The Development and Evaluation of an "E-Visit" Program for the Management of Acne

NCT00417456
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Evisit, Office visit
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Sep 5, 2026, 10:10 AM EDT
Completed Phase 3 Interventional

Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris

NCT02865005
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Dapsone 5.0% Gel (SEEGPharm), Placebo, Dapsone 5.0% Gel (Allergan)
Drug · Other
Lead sponsor
Seegpharm S.A.
Industry
Eligibility
12 Years to 40 Years
Enrollment
2,361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
35
States / cities
Encino, California • Fullerton, California • La Mesa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2016 · Synced Sep 5, 2026, 10:10 AM EDT
Completed Not applicable Interventional

Comparison of the RevLite Electro-optic Q-Switched Neodymium-doped Yttrium Aluminium Garnet (EO QS Nd:YAG) Laser to a Fractionated Laser System

NCT00955461
View directory record Official record
Conditions
Photodamage, Irregular Pigmentation, Acne Scars
Interventions
RevLite laser treatment, Fractionated Laser treatment
Procedure
Lead sponsor
ConBio, a Cynosure Company
Industry
Eligibility
25 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2012 · Synced Sep 5, 2026, 10:10 AM EDT
Completed Phase 1 Interventional

Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison With Tazorac Cream

NCT02849873
View directory record Official record
Conditions
Acne
Interventions
IDP-123 Lotion, Tazorac Cream
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Sep 5, 2026, 10:10 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Acne Vulgaris With Doryx Tablets Compared to Doxycyline Hyclate

NCT00635609
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Doxycycline hyclate (Doryx), Doxycycline hyclate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
12 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
4
States / cities
Vista, California • Miami, Florida • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Sep 5, 2026, 10:10 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

NCT06840392
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
35
States / cities
Birmingham, Alabama • Gilbert, Arizona • Fremont, California + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 5, 2026, 10:10 AM EDT
Completed Phase 4 Interventional Results available

A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)

NCT04451330
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene cream, Doxycycline hyclate, Trifarotene Vehicle, Doxycycline Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
25
States / cities
Fort Smith, Arkansas • Hot Springs, Arkansas • Rogers, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Sep 5, 2026, 10:10 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Impact of Clascoterone 1% Cream on Skin Barrier Properties in Acne Prone Patients

NCT06415292
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Winlevi (clascoterone) 1% cream
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Sep 5, 2026, 10:10 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Epidermal Delivery of Ani-Aging Ingredients

NCT01847066
View directory record Official record
Conditions
Wrinkles, Acne Scars, Pigmentation
Interventions
Erbium 2940 plus cosmetics plus Impact, Erbium 2940 plus cosmetics
Device
Lead sponsor
Alma Lasers Inc.
Industry
Eligibility
35 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2013 · Synced Sep 5, 2026, 10:10 AM EDT
Completed Not applicable Interventional

Teledermatology and Modulation of Antibiotic Dose in Acne Vulgaris

NCT02905851
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Feedback group, Non Feedback group
Other
Lead sponsor
University of California, Davis
Other
Eligibility
15 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Sep 5, 2026, 10:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

SkinPen Efficacy on Acne Scars on the Face and/or Back

NCT02646917
View directory record Official record
Conditions
Atrophic Acne Scar
Interventions
Aesthetic Microneedling Treatment
Procedure
Lead sponsor
Bellus Medical, LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Sep 5, 2026, 10:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.

NCT00651469
View directory record Official record
Conditions
Acne Vulgaris
Interventions
YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
14 Years to 45 Years · Female only
Enrollment
534 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
27
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2014 · Synced Sep 5, 2026, 10:10 AM EDT
Withdrawn Phase 2Phase 3 Interventional Accepts healthy volunteers

Topical 5% Tranexamic Acid as a Treatment for Postinflammatory Hyperpigmentation Due to Acne Vulgaris

NCT03361345
View directory record Official record
Conditions
Postinflammatory Hyperpigmentation
Interventions
Tranexamic Acid, Vehicle
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Dearborn, Michigan
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Sep 5, 2026, 10:10 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Clinical Trial in Subjects With Mild to Moderate Acne Vulgaris

NCT02832063
View directory record Official record
Conditions
Acne Vulgaris
Interventions
B244, Placebo
Biological
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Sep 5, 2026, 10:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris

NCT03664739
View directory record Official record
Conditions
Acne Vulgaris
Interventions
IDP-120 Gel, IDp-120 Vehicle Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years and older
Enrollment
608 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
25
States / cities
Mobile, Alabama • Hot Springs, Arkansas • Beverly Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Sep 5, 2026, 10:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-label Safety and Tolerability Study of LTS-PDT in Healthy Volunteers

NCT01830764
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Red Light (PDT)
Drug
Lead sponsor
Dermira, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Sep 5, 2026, 10:10 AM EDT
Completed Not applicable Interventional

Safety & Effectiveness of the BEAM Device in Mild-to-moderate Acne

NCT01162837
View directory record Official record
Conditions
Acne
Interventions
BEAM device
Device
Lead sponsor
Oregon Aesthetic Technologies
Industry
Eligibility
15 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Miami Beach, Florida • Warren, Michigan • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 2, 2012 · Synced Sep 5, 2026, 10:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa

NCT03275870
View directory record Official record
Conditions
Hidradenitis Suppurativa, Hidradenitis, Acne Inversa, Boils, Follicular Occlusion Triad, Follicular Occlusion Tetrad
Interventions
Hydroxychloroquine
Drug
Lead sponsor
Elena Gonzalez Brant, MD
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Sep 5, 2026, 10:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers

NCT01115322
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene Foam without irradiation, Tazarotene Foam with UVA and UVB irradiation, Tazarotene Foam with UVA, UVB, and visible light, Vehicle Foam without irradiation, Vehicle Foam with UVA and UVB irradiation, Vehicle Foam with UVA and UVB and visible light irradiation, No Treatment without irradiation, No Treatment with UVA and UVB irradiation, No Treatment with UVA and UVB and visible light irradiation
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Sep 5, 2026, 10:10 AM EDT